Clinical Trial Update: Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial combining oxaliplatin, capecitabine, and celecoxib with concurrent radiation for rectal cancer was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• CELEBREX (Celecoxib)
• Eloxatin (oxaliplatin)
• Xeloda (capecitabine)

Snippet

Sponsor: New Mexico Cancer Research Alliance | Conditions: Rectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-09-01